Resonance Specialties Ltd-$
UNAUDITED FINANCIAL RESULTS FOR Q1 FY27
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 04 Aug 2026, 12:11 PM IST · BSE ID: a8d0aa68-1951-4b55-a093-b27875354be7
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest quarterly financial results and plans to buy a factory from a related company for Rs. 29.98 crores.
🤖 AI Summary
- Resonance Specialties reported unaudited revenue from operations of Rs. 3,258.41 Lakhs for Q1 FY27.
- Net profit for the quarter ended June 30, 2026, was Rs. 574.42 Lakhs, up 252.32% YoY.
- Board approved the acquisition of a Mandideep manufacturing facility from Kaygee Laboratories Private Limited for Rs. 29.98 crores.
- The acquisition is from a promoter group company, Kaygee Laboratories Private Limited, on a slump sale basis, subject to shareholder approval.
- Expected completion of the manufacturing facility purchase is on or before November 30, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Revenue from operations (Q1 FY27)
3,258.41 Lakhs
Profit for the period (Q1 FY27)
574.42 Lakhs
252.32
Acquisition Consideration
29.98 crores
🏢 How This Affects the Company
Acquiring the Mandideep manufacturing unit aims to secure uninterrupted production of chemical intermediates and APIs, crucial for the company's end products, by integrating a long-term supplier facility.
The Rs. 29.98 crores cash consideration for the acquisition will impact the company's cash reserves and balance sheet structure upon completion. Eliminating outsourcing costs for manufacturing activities could improve future margins.
The acquisition will enhance operational control and efficiency by bringing in-house the manufacturing of chemical intermediates and APIs, which were previously supplied on a job work basis. This facility is WHO, Geneva approved.
The acquisition converts an existing supplier relationship into an owned asset, potentially reducing supply chain risks associated with outsourcing. The transaction is with a related party, though stated to be at arm's length based on a valuation certificate.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the proposed acquisition of the manufacturing facility from Kaygee Laboratories Private Limited.
👤
Who Is Affected
All shareholders are affected as their approval is required for the Rs. 29.98 crores acquisition from a promoter group company, Kaygee Laboratories Private Limited.
🔍
Management Signal
Management intends to vertically integrate a critical manufacturing facility to secure supply, enhance efficiency, and reduce outsourcing costs.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder meeting date for approval of the Mandideep facility acquisition.
Progress on the agreement for purchase of the Mandideep manufacturing unit.
Updates on the expected completion date of the acquisition by November 30, 2026.
MEDIUM RISK
The acquisition from a related party for Rs. 29.98 crores requires shareholder approval, introducing a dependency for deal completion.
💡 Investor Takeaway
Resonance Specialties reported a Q1 FY27 revenue from operations of Rs. 3,258.41 Lakhs, a 53.16% increase YoY. Net profit for the period rose by 252.32% to Rs. 574.42 Lakhs. The Board approved the purchase of a manufacturing facility for Rs. 29.98 crores from a promoter group company, subject to shareholder approval.
⚖️ Strengths & Concerns
✅ Positives
- Q1 FY27 Revenue from operations increased by 53.16% to Rs. 3,258.41 Lakhs compared to Rs. 2,127.42 Lakhs in Q1 FY26.
- Profit for the period significantly grew by 252.32% to Rs. 574.42 Lakhs in Q1 FY27 from Rs. 163.04 Lakhs in Q1 FY26.
⚠️ Concerns
- The acquisition of the manufacturing facility for Rs. 29.98 crores is from a related party, Kaygee Laboratories Private Limited, requiring shareholder approval.
- The agreement for purchase has not yet been entered into, with the expected completion by November 30, 2026, subject to various consents.
📅 Company Track Record
Resonance Specialties Ltd. previously reported FY26 revenue at Rs. 9,024.75 Lakhs with profit up 58.38% YoY, and recommended a Rs. 1 dividend. Q1 FY27 revenue of Rs. 3,258.41 Lakhs builds on the prior year's performance.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Resonance Specialties' revenue from operations in Q1 FY27?
Resonance Specialties reported revenue from operations of Rs. 3,258.41 Lakhs for the quarter ended June 30, 2026.
What was the net profit for Resonance Specialties in Q1 FY27?
The profit for the period for Resonance Specialties in Q1 FY27 was Rs. 574.42 Lakhs, compared to Rs. 163.04 Lakhs in Q1 FY26.
What manufacturing facility is Resonance Specialties planning to acquire?
Resonance Specialties plans to acquire a manufacturing facility located at Plot No. 6, New Industrial Area-II, Mandideep, Dist Raisen- 462046, Madhya Pradesh.
What is the consideration for the Mandideep manufacturing facility acquisition?
The consideration payable for the manufacturing facility purchase is Rs. 29.98 crores on a slump sale basis.
Who is the seller of the manufacturing facility to Resonance Specialties?
The seller of the manufacturing facility is M/s. Kaygee Laboratories Private Limited, a company belonging to the promoter group.
Questions based on this BSE filing only. For information purposes.